These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22555662)

  • 1. Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression.
    Noordermeer SM; Monteferrario D; Sanders MA; Bullinger L; Jansen JH; van der Reijden BA
    Blood; 2012 May; 119(18):4335-7. PubMed ID: 22555662
    [No Abstract]   [Full Text] [Related]  

  • 2. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
    Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Shiba N; Ohki K; Hayashi Y; Yamashita Y; Shimada A; Tanaka S; Adachi S
    Haematologica; 2014 Nov; 99(11):e225-7. PubMed ID: 25015941
    [No Abstract]   [Full Text] [Related]  

  • 5. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
    Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
    Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
    Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
    Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
    Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myelocytic leukemia with t(11;17)(q23;q12-q21) involves a fusion of MLL and AF17.
    Moore SD; Strehl S; Dal Cin P
    Cancer Genet Cytogenet; 2005 Feb; 157(1):87-9. PubMed ID: 15676155
    [No Abstract]   [Full Text] [Related]  

  • 10. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
    Ho PA; Alonzo TA; Gerbing RB; Pollard JA; Hirsch B; Raimondi SC; Cooper T; Gamis AS; Meshinchi S
    Br J Haematol; 2013 Sep; 162(5):670-7. PubMed ID: 23826732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients.
    Noordermeer SM; Sanders MA; Gilissen C; Tönnissen E; van der Heijden A; Döhner K; Bullinger L; Jansen JH; Valk PJ; van der Reijden BA
    Blood; 2011 Nov; 118(20):5613-21. PubMed ID: 21937695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated EVI1 expression in myeloid malignancies.
    Pardanani A
    Leuk Lymphoma; 2006 Dec; 47(12):2443-4. PubMed ID: 17169788
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.
    Smol T; Nibourel O; Marceau-Renaut A; Celli-Lebras K; Berthon C; Quesnel B; Boissel N; Terré C; Thomas X; Castaigne S; Dombret H; Preudhomme C; Renneville A
    Leuk Res; 2015 Dec; 39(12):1443-7. PubMed ID: 26467814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
    Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
    Weisser M; Kern W; Schoch C; Tschulik C; Hiddemann W; Haferlach T; Schnittger S
    Leuk Lymphoma; 2006 Dec; 47(12):2645-7. PubMed ID: 17169810
    [No Abstract]   [Full Text] [Related]  

  • 16. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Marcotegui N; Conchillo A; Guruceaga E; Roman-Gomez J; Calasanz MJ; Agirre X; Prosper F; Odero MD
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):E167-8; author reply E169-70. PubMed ID: 20930122
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells.
    Eguchi-Ishimae M; Eguchi M; Ohyashiki K; Yamagata T; Mitani K
    Int J Hematol; 2009 Mar; 89(2):253-256. PubMed ID: 19241117
    [No Abstract]   [Full Text] [Related]  

  • 18. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
    Su G; Lian X; Tan D; Tao H; Liu H; Chen S; Yin H; Wu D; Yin B
    Leuk Lymphoma; 2015 Feb; 56(2):472-9. PubMed ID: 24828867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
    Nucifora G; Rowley JD
    Blood; 1995 Jul; 86(1):1-14. PubMed ID: 7795214
    [No Abstract]   [Full Text] [Related]  

  • 20. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
    Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
    Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.